Bob Manam, MD
Infectious Disease · Aurora, ILNPI 1063443885
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 4 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 4 manufacturers reported payments, led by AstraZeneca at 48.4% of the total. Reporting peaked in 2021 at $103 and has fallen 67.8% since, to $33 in 2025. That places this record below the midpoint for infectious disease clinicians in IL, where the typical reported total is $182.
Across 4 payments — averaging $53.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$103
- Kerecis Limited$59
- Aerin Medical Inc.$33
- Otsuka America Pharmaceutical, Inc.$18
What the payments were for
- Food & beverage$213100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 1 | $103 |
| Kerecis Limited | 1 | $59 |
| Aerin Medical Inc. | 1 | $33 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$103
How this compares
$213 in reported general payments places this provider in the 50th percentile of 368 infectious disease providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 11 | $43,259 |
| TivicayDolutegravir Sodium | 12 | $31,425 |
| DescovyEmtricitabine/Tenofov Alafenam | 12 | $30,658 |
| ErtapenemErtapenem Sodium | 22 | $10,632 |
| CeftriaxoneCeftriaxone Sodium | 38 | $3,097 |
| Daptomycin | 15 | $3,049 |
| Meropenem | 12 | $1,584 |
| Cefazolin Sodium | 28 | $1,328 |
| CefuroximeCefuroxime Axetil | 31 | $1,146 |
| Ampicillin-SulbactamAmpicillin Sod/Sulbactam Sod | 39 | $1,055 |
| Cephalexin | 79 | $783 |
| Vancomycin Hcl | 18 | $578 |
| Doxycycline Hyclate | 16 | $335 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 11 | $266 |
| Metronidazole | 14 | $172 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Aurora
- Frank PalellaChicago$987K
- Jeffrey ShermanDeerfield$527K
- Catherine CreticosChicago$335K
- Babafemi TaiwoChicago$292K
- Beverly ShaChicago$202K
- Chad ZawitzChicago$193K
- Nancy GlickChicago$186K
- Kamaljit SinghChicago$138K
- Jorge ParadaMaywood$128K
- James SullivanChicago$100K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.